Thierry Facon, MD, details the rationale for evaluating Isa-VRd in patients with transplant-ineligible, newly diagnosed multiple myeloma.
Thierry Facon, MD
Advertisement
Thierry Facon, MD, is a professor of hematology in the Department of Hematology at Lille University Hospital in France.
Articles by Thierry Facon, MD
Dr Facon on the Implications of Isatuximab Plus VRd in Transplant-Ineligible Newly Diagnosed Myeloma
Thierry Facon, MD, discusses clinical implications from the phase 3 IMROZ trial
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
HERIZON-GEA-01 PD-L1 Subgroup Data Support Zanidatamab Combo as a New Frontline SOC in HER2+ GEA
2
Selinexor Plus Ruxolitinib Yields Superior Spleen Responses, OS Signal in JAK Inhibitor–Naïve Myelofibrosis
3
TALAPRO-3 Shows Talazoparib Plus Enzalutamide Improves rPFS in HRR-Altered mCSPC
4
Antibody-Drug Conjugates in Lung Cancer: The Tip of the Iceberg
5